Fate Therapeutics

Science

Publications & Presentations

ASCO 2026 Presentations
Preliminary Phase 1 Results of a MICA/B-targeted CAR T cell Designed to Overcome Solid Tumor Escape Mechanisms and Avoid the Requirement for Conditioning Chemotherapy
ASGCT 2026 Presentations
FT839: A Multi-Antigen Targeting Off-the-Shelf Dual-CAR T Cell for the Treatment of Pathogenic B and T Cells in Autoimmune Diseases
FT819 Drives B cell Compartment Remodeling of Patients with Systemic Lupus Erythematosus Without Conditioning Chemotherapy
CAR T cells Targeting pan-Tumor Antigens MICA/B can be Uniquely Combined with SOC Treatments without Conditioning Chemotherapy for Broad and Effective Therapeutic Application in Cancer
CCR East 2026 Presentation
Safety and Efficacy of an Off-the-Shelf Anti-CD19 CAR T-Cell Therapy With Reduced Conditioning in SLE: A Phase 1 Study
Pediatric Rheumatology Symposium 2026 Presentation
Off-the-Shelf Anti-CD19 CAR T-cell Therapy With Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
ASH 2025 Presentations
Development of Next Generation Multi-Antigen Targeting Off-the Shelf CAR T-Cells for Conditioning-Free Treatment of B-Cell Lymphoma
The Development of and Off-the-Shelf CAR T-Cell Therapy Targeting CD19 and CD38 for Broad Application in Autoimmune Disease
Targeting of Tumor Antigen CD38 and Stress Antigens MICA/B by CAR T-Cells Provides a Unique Approach for the Comprehensive Treatment of Multiple Myeloma
EULAR 2025 Presentations
Next-Generation Off-the-Shelf CAR T-Cells: A Novel Platform to Enable Comprehensive Elimination of Aberrant Effector Cells for the Treatment of Autoimmune Diseases in the Absence of Conditioning Chemotherapy
Next Generation CAR-NK cell Therapy Leverages Alloimmune Defense Technology to Persist Without Conditioning Chemotherapy for the Treatment of Autoimmune Disease
Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
ASGCT 2025 Presentations
FT836, a Novel MICA/B-targeting CAR T-cell Therapy Engineered to Eliminate the Need for Conditioning Chemotherapy with Broad Activity Across Solid Tumor Indications
Targeting uPAR with Multiplexed-Engineered iPSC-Derived CAR T Cells to Reverse Age- and Insult-Related Fibrotic Disease
Next-Generation Off-the-Shelf CAR T-Cell Therapies for Conditioning-Free Treatment of a Broad Spectrum of In collaboration with Autoimmune Diseases and Hematologic Malignancies
Alloimmune Defense Receptor Combined with Genetic Ablation of Adhesion Ligand CD58 is a Comprehensive Approach to Promote Functional Persistence of Allogeneic Cell Therapies without Conditioning Chemotherapy
Phase 1 Translational Assessment of an Off-The-Shelf CAR NK Cell Armed with Alloimmune Defense Technology for Conditioning-free Therapy
2024 ASGCT Poster Presentation
FT522: A CAR NK Cell with the Unique Ability to Target Multiple Pathogenic Cell Types and Circumvent Lympho-conditioning in Systemic Autoimmunity
FT819-102: Clinical Translation of Off-the-Shelf TCR-less CD8αβ+ anti-CD19 CAR-T Cells for The Treatment of B cell-mediated Autoimmune Disorders
2022 ASH Presentation
High-Density Cryopreservation of Off-the-Shelf CAR Cells Facilitates On-demand Treatment Access
Alloimmune Defense Receptor Redirects Host Immune Cell Alloreactivity to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf Cell-Based Cancer Therapy
A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape
Off-the-Shelf CAR-NK cell Therapy co-Targeting GPRC5D and CD38 for the Treatment of Multiple Myeloma
CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium With the Hematopoietic Lineage Potency to Give Rise To Bona Fide Lymphocytes
iPSC-derived CD38-null NK Cells in Combination with CD38-targeted Antibody: a Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection
Characterization of Engineered Macrophages and other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells
A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogeneous Population Associated with AML
Multi-Antigen Targeting by Novel Combination of CAR-T Cells and hnCD16 Transgene Yields in Complete Tumor Clearance via Antibody Dependent Cellular Cytotoxicity
The Development of Allogeneic Tips-Derived TCR- CAR+ CD8⍺β T Cells
2022 SITC Presentation
iPSC-derived NK cells Engineered with a Novel TGFβ signal Redirector Receptor Exhibit Enhanced Performance Against Solid Tumors
Trimodal CAR+TCR+hnCD16+ iPSC-derived T Cells Co-Targeting Surface and Intracellular/Neoantigens Demonstrate Additive Effect on Overcoming Tumor Heterogeneity and Cancer Escape
Novel Immune Reconstitution Model Highlights the Importance of Stealth Strategies that Potentiate Effector Cell Function and Promote Functional Persistence of Next-Generation Adoptive Cell Therapies
Off-the-Shelf iPSC-derived CAR-T cells Targeting KLK2 Demonstrate Prolonged Tumor Control and Survival in Xenograft Models of Prostate Cancer
Off-the-Shelf iPSC-derived CAR-T cells Containing Seven Functional Edits Overcome Antigen Heterogeneity, Improve Trafficking, and Withstand Immunosuppression Associated with Failed Tumor Treatment
Engineering of Synthetic Chemokine Receptors into iPSC-derived CAR-T cells to Increase Homing and Enhance Trafficking into Solid Tumors
Preclinical in vivo Model Development: Highlighting Success and Discussing Xenograft Advancements, a Step Closer in Predicting Patient Outcomes
2022 AACR Presentation
A novel synthetic stealth receptor that redirects host immune cell alloreactivity and potentiates functional persistence of adoptively transferred off-the-shelf cell-based cancer therapy
Chimeric CD3 Fusion Receptors Expressed on iPSC-derived Universal TCR-less CAR-T and -NK Cells Synergize with Bispecific Engagers to Enhance Antitumor Activity and Limit Antigen Escape
Novel Combination of iPSC-derived Dual Dual -CAR NK Cells with CD16 Fc Receptor for Multi-antigen Targeting of Multiple Myeloma to Overcome Clonal Resistance and Antigen Escape
Multiplexed-engineered, iPSC-derived T Cells Expressing Three Unique Targeting Modalities Address Tumor Heterogeneity and Antigen Escape
Detection of Genetically Engineered iPSC-derived Natural Killer Cells in Blood and Tissue
2022 ASGCT Presentation
Long-term Stability Assessment of Cryopreserved iPSC-derived T and NK Cells Supports Mass Production and Off-the-shelf Therapeutic Applications
Long-term Stability of iPSC-Derived CD34+ Cell Banks Supports the Sustainable Manufacture of Off-the-shelf Immunotherapies
Development of Next-Generation, Off-the-Shelf CAR T-cell Immunotherapies for Solid Tumors
Development of Master Multiplexed-Engineered iPSC Bank for Off-the-Shelf Cell-Based Cancer Immunotherapy with Reduced Conditioning Chemotherapy
10-year Stability Assessment of Cryopreserved, Engineered iPSC Banks: Genetic and Phenotypic Characterization
Robust T-cell Cellular Reprogramming and Single-cell Engineering Platform Overcomes Inconsistencies and Heterogeneity Associated with Engineering Primary T cells
iPSC-derived CD38-null NK cells in Combination with CD38-targeted Antibody Represent a Novel Therapeutic Strategy to Reduce the Requirement of Conditioning Chemotherapy for Off-the-Shelf Cell-based Cancer Immunotherapy

MENU